A special congressional committee has recommended a $15 billion investment to boost the United States' biotech advantage over ...

ABL Bio Inc., a South Korean biotech company, will license out its proprietary blood-brain barrier shuttle platform, called ...

Reports FY24 revenue GBP 128.8M vs. GBP 89.5M last year. Frank Mathias, CEO of OXB, commented: “2024 was a year of strong commercial progress for ...

ABL Bio enters Grabody-B brain delivery platform license pact with GSK to develop novel medicines for neurodegenerative diseases: Seongnam, South Korea Tuesday, April 8, 2025, 17: ...

Programs will leverage ABL Bio's Grabody-B platform technology to deliver molecules across the blood-brain barrier.

In a jobs market marred by a hiring slowdown, Staffline (STAF) appears to be bucking the trend. Unlike its larger peers, the Aim-listed blue-collar recruiter grew revenue, underlying operating profits ...

ABL Bio Inc., a South Korean biotech company, will license out its proprietary blood-brain barrier shuttle platform, called ...

ABL Bio Inc. announced April 7 that it sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, ...

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across the blood-brain barrier.

South Korean clinical-stage biotech ABL Bio (Kosdaq: 298380) on Sunday announced a worldwide licensing agreement enabling GSK (LSE: GSK) to develop novel medicines for neurodegenerative diseases by ...

ABL Bio's Grabody-B was developed to overcome the limitations of existing drugs that have difficulty crossing the BBB by targeting the Insulin-like Growth Factor 1 Receptor (IGF1R), facilitating drug ...

GSK's clinical-stage pipeline is currently focused on oncology, respiratory, immunology and inflammation, and infectious ...